Abstract Background The Human papillomavirus (HPV) vaccine has been available for
protection against HPV-associated cervical cancer and genital warts since 2006 …

The recent FDA approval of sipuleucel-T (Provenge®), a patient-specific immunotherapy for
androgen-independent prostate cancer developed by Dendreon Corporation, has provided …

A wide variety of inflammatory diseases temporally associated with the administration of
various vaccines, has been reported in the literature. A PubMed search from 1979 to 2013 …

Cervical cancer still poses a significant global challenge. Developed countries have
mitigated this challenge by the introduction of structured screening programmes and, more …

Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …

In preparation for the introduction of human papillomavirus (HPV) vaccine, we investigated
awareness and knowledge of HPV/HPV vaccine and potential acceptability to HPV vaccine …

The development of a massively producible vaccine against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the …

Background: In 2007, Australia implemented the National human papillomavirus (HPV)
Vaccination Program, which provides quadrivalent HPV vaccine free to all women aged 12 …

Cervical cytology screening has reduced cervical cancer morbidity and mortality but shows
important shortcomings in terms of sensitivity and specificity. Infection with distinct types of …

Highlights•Recent advances in bionanotechnology are poised to have a major impact on
vaccines.•Synthetic particulate vaccines offer advantages for precisely engineered …